| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain therapeutics designed to minimize abuse and overdose risk, has released video highlights from its widely attended symposium at PAINWeek2025, the world's largest pain management conference.
The event, titled "Pain Management, RE-Invented: A New Era for Analgesia," was held in Las Vegas on September 3, 2025, and featured a distinguished panel of medical and scientific leaders. Together, they examined the urgent challenges in today's pain treatment landscape and the promising potential of Ensysce's proprietary platforms, TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance).
These breakthrough technologies aim to redefine opioid safety by preventing misuse and overdose while maintaining effective pain relief - a critical advancement as the opioid crisis continues to impact communities globally.
Posted In: ENSC
